NYSEAMERICAN:PTN - Palatin Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.43 -0.21 (-12.80 %) (As of 05/19/2019 10:18 AM ET)Previous Close$1.43Today's Range$1.14 - $1.7452-Week Range$0.59 - $1.74Volume15.05 million shsAverage Volume1.25 million shsMarket Capitalization$290.38 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey. Receive PTN News and Ratings via Email Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone+1-609-4952200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees19 Outstanding Shares203,063,000Market Cap$290.38 million Next Earnings Date9/12/2019 (Estimated) OptionableNot Optionable Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions What is Palatin Technologies' stock symbol? Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN." How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. View Palatin Technologies' Earnings History. When is Palatin Technologies' next earnings date? Palatin Technologies is scheduled to release their next quarterly earnings announcement on Thursday, September 12th 2019. View Earnings Estimates for Palatin Technologies. What price target have analysts set for PTN? 2 brokerages have issued twelve-month target prices for Palatin Technologies' shares. Their forecasts range from $2.75 to $6.00. On average, they expect Palatin Technologies' share price to reach $4.3750 in the next year. This suggests a possible upside of 205.9% from the stock's current price. View Analyst Price Targets for Palatin Technologies. What is the consensus analysts' recommendation for Palatin Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies. What are Wall Street analysts saying about Palatin Technologies stock? Here are some recent quotes from research analysts about Palatin Technologies stock: 1. According to Zacks Investment Research, "Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies. " (4/17/2019) 2. HC Wainwright analysts commented, "Our thesis on shares remains unchanged; major boxes checked and valuation disconnect exists, in our belief. Significant boxes have already been checked off, which we believe provide a derisked opportunity for investors." (1/11/2019) Has Palatin Technologies been receiving favorable news coverage? News headlines about PTN stock have trended positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Palatin Technologies earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting Palatin Technologies? Palatin Technologies saw a decline in short interest during the month of April. As of April 15th, there was short interest totalling 15,028,662 shares, a decline of 2.9% from the March 29th total of 15,482,227 shares. Based on an average daily volume of 1,129,731 shares, the days-to-cover ratio is currently 13.3 days. Currently, 7.8% of the company's stock are short sold. View Palatin Technologies' Current Options Chain. Who are some of Palatin Technologies' key competitors? Some companies that are related to Palatin Technologies include Integral Diagnostics (IDX), Senseonics (SENS), Senseonics (SENS), Akumin (AKU), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), Sernova (SVA), SQI Diagnostics (SQD), Dorsavi (DVL) and GeneNews (GEN). What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), Points International (PCOM), Progenics Pharmaceuticals (PGNX), 5Barz International (BARZ), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX), Catalyst Pharmaceuticals (CPRX) and ImmunoGen (IMGN). Who are Palatin Technologies' key executives? Palatin Technologies' management team includes the folowing people: Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 65)Dr. Carl Spana, Co-Founder, Pres, CEO & Director (Age 57)Mr. Stephen T. Wills CPA, CPA, MST, CFO, COO, Exec. VP, Treasurer & Sec. (Age 62)Burns McClellan, VP of Investor Relations Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.93%), Acadian Asset Management LLC (1.30%), Strs Ohio (0.29%), Wells Fargo & Company MN (0.16%), State of Wisconsin Investment Board (0.13%) and The Manufacturers Life Insurance Company (0.07%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies. Which institutional investors are selling Palatin Technologies stock? PTN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Oxford Asset Management LLP, Strs Ohio and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Palatin Technologies. Which institutional investors are buying Palatin Technologies stock? PTN stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, SG Americas Securities LLC, Wells Fargo & Company MN, State of Wisconsin Investment Board, BNP Paribas Arbitrage SA and Virtu Financial LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies. How do I buy shares of Palatin Technologies? Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $1.43. How big of a company is Palatin Technologies? Palatin Technologies has a market capitalization of $290.38 million. Palatin Technologies employs 19 workers across the globe. What is Palatin Technologies' official website? The official website for Palatin Technologies is http://www.palatin.com/. How can I contact Palatin Technologies? Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200. MarketBeat Community Rating for Palatin Technologies (NYSEAMERICAN PTN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 234 (Vote Underperform)Total Votes: 540MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.